346 reports of this reaction
1.7% of all METHOXY POLYETHYLENE GLYCOL EPOETIN BETA reports
#9 most reported adverse reaction
ANAEMIA is the #9 most commonly reported adverse reaction for METHOXY POLYETHYLENE GLYCOL EPOETIN BETA, manufactured by Vifor (International) Inc.. There are 346 FDA adverse event reports linking METHOXY POLYETHYLENE GLYCOL EPOETIN BETA to ANAEMIA. This represents approximately 1.7% of all 19,964 adverse event reports for this drug.
Patients taking METHOXY POLYETHYLENE GLYCOL EPOETIN BETA who experience anaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ANAEMIA is a less commonly reported adverse event for METHOXY POLYETHYLENE GLYCOL EPOETIN BETA, but still significant enough to appear in the safety profile.
In addition to anaemia, the following adverse reactions have been reported for METHOXY POLYETHYLENE GLYCOL EPOETIN BETA:
The following drugs have also been linked to anaemia in FDA adverse event reports:
ANAEMIA has been reported as an adverse event in 346 FDA reports for METHOXY POLYETHYLENE GLYCOL EPOETIN BETA. This does not prove causation, but indicates an association observed in post-market surveillance data.
ANAEMIA accounts for approximately 1.7% of all adverse event reports for METHOXY POLYETHYLENE GLYCOL EPOETIN BETA, making it a notable side effect.
If you experience anaemia while taking METHOXY POLYETHYLENE GLYCOL EPOETIN BETA, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.